COMMUNIQUÉS West-GlobeNewswire

Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR¹ by December 2025, Fastest Supplement Brand Growth in Industry History
10/11/2025
Total Revenue Surges 568% YoY to $23.6 million ; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M Monthly Revenue or $ [...]
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
10/11/2025
Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, subject to market [...]
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
10/11/2025
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026 [...]
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
10/11/2025
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months [...]
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
10/11/2025
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month [...]
Orbus Therapeutics Announces Oral Presentation of Updated Results With Blinded Independent Central Review from the Phase 3 STELLAR Clinical Trial at the Society for Neuro-Oncology Annual Meeting
10/11/2025
PALO ALTO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orbus Therapeutics, Inc., a private pharmaceutical company, today announced it will present updated results from the Phase 3 STELLAR trial investigating eflornithine [...]
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
10/11/2025
Third Quarter Revenues of $ 47 . 0 Million, up 13 % Year-over-Year, and Adjusted EBITDA of $11. 7 Million, up 34 % Year-Over Year Nine Month Revenue of $135. 8 Million, up 11% Year-over-Year; Adjusted EBITDA of $ 34 . 2 [...]
Galecto Announces Acquisition of Damora Therapeutics
10/11/2025
Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative Neoplasms [...]
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
10/11/2025
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a [...]
ONL Therapeutics to Present at EYENOVATE and the FLORetina–ICOOR Congress 2025
10/11/2025
ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today [...]
ITM to Participate in Upcoming Investor Conferences
10/11/2025
Garching / Munich, Germany, November 10, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in upcoming industry investor conferences and [...]
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
10/11/2025
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the [...]
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
10/11/2025
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of [...]
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
10/11/2025
EVerZom’s investigational drug candidate EViv, developed to treat ACLF, using its proprietary exosome platform, represents a novel approach to regenerative therapies Pending successful in vivo proof-of-concept results, [...]
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF
10/11/2025
Le candidat-médicament expérimental EViv d'EVerZom, développé pour le traitement de l'ACLF en utilisant sa plateforme propriétaire d'exosomes, représente une approche novatrice en matière de thérapies régénératives En [...]
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
10/11/2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease models Safety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo [...]
GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N dans le traitement de l’ACLF dans le cadre du Liver Meeting® 2025
10/11/2025
Des études précliniques ont démontré une efficacité significative sur l'inflammation systémique et le fonctionnement des organes dans des modèles pathologiques d'ACLF. Des données de sécurité issues de l’étude de Phase [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
10/11/2025
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal PPMS study (FENtrepid), fenebrutinib [...]
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network
10/11/2025
TRIAL TO BE CONDUCTED BY ADVANCE-ID, A NATIONAL UNIVERSITY OF SINGAPORE LED TRIAL NETWORK, IN PARTNERSHIP WITH BIOVERSYS Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- [...]

Pages